Orsini and Paynela Join Forces to Enhance Access to Care for Rare Disease Patients

Orsini and Paynela: A New Era in Patient Support for Rare Diseases

In a groundbreaking collaboration, Orsini, recognized as a leader in rare disease pharmacy solutions, has joined forces with Paynela, a health technology company that specializes in creating affordable healthcare solutions. Together, they aim to significantly enhance the affordability and efficacy of copay and coinsurance support programs specifically designed for patients suffering from rare diseases.

Understanding the Need for Accessibility

Patients with rare diseases often encounter significant obstacles when it comes to accessing necessary therapies. These barriers include high out-of-pocket expenses and complex financial processes that can deter individuals from pursuing the treatments they need. This collaboration seeks to address the urgent need for efficient, patient-centered solutions that ease these financial burdens.

Both companies highlight that financial assistance is critical in helping patients navigate the often-overwhelming costs associated with specialty medications. With the integration of Paynela's cutting-edge technology, which utilizes artificial intelligence for claims processing and patient fund management, Orsini aims to bolster the support offered to biopharma partners, thereby ensuring that underserved patient populations can secure the treatments they desperately require.

Innovative Technology at Work

Incorporating AI-driven solutions, the collaboration leverages several key tools that streamline the financial assistance process:

1. NelaClaim: An AI-driven claims processing engine that optimizes the speed and accuracy of claims adjudication, allowing patients to receive their funds promptly.

2. NelaPay: Offers direct-to-patient payment options, ensuring that individuals receive all of their funding quickly and on their terms.

3. NelaView: A user-friendly patient portal that empowers patients to manage their affordability funds easily.

4. NelaHub: A financial services hub that assesses patients' eligibility for financial assistance and delivers funds directly to them without delay.

By integrating these services, Orsini and Paynela effectively shift the landscape of financial assistance, making it more accessible and manageable for those most in need.

Statements from Leadership

Brandon Tom, CEO of Orsini, expressed the company’s commitment to alleviating the financial challenges faced by patients. He stated, "We recognize the critical need for streamlined financial assistance solutions that help our biopharma partners reduce the burden on patients navigating complex healthcare costs. By incorporating Paynela's AI-driven affordability technology, we empower patients to manage their out-of-pocket costs for specialty therapies and stay connected to the care they need."

On the other side, Mary-Beth Macaluso, CEO of Paynela, emphasized their shared mission to enhance access to life-saving therapies. "Partnering with Orsini allows us to bring our automated affordability solutions to patients who need them most—those living with rare diseases. Together, we're delivering smarter, more efficient affordability solutions for our biopharma partners while ensuring patients can access the medications they need."

Conclusion

The fusion of Orsini's extensive experience in rare disease pharmacy solutions with Paynela’s innovative technology ushers in a new era for patient support. This partnership not only enhances the affordability of therapies for those affected by rare diseases but also redefines the patient experience, ensuring that no one is left behind. As both companies move forward, they will continue to focus on delivering comprehensive, compassionate care that addresses the unique challenges faced by patients and their families in navigating the healthcare landscape.

For additional information on this partnership and the innovations being introduced, visit Orsini's website and Paynela's website.